J&J: unveils results of Impella ECP trial

(CercleFinance.com) - J&J announces that the results of the first pivotal trial of Impella ECP - a novel transvalvular axial flow pump - were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference.


Conducted by Abiomed, a Johnson & Johnson MedTech company, the trial included 256 patients across 18 sites in the USA, and met its primary objective with a major adverse cardiac and cerebrovascular event (MACCE) rate of 6.3% at 30 days, well below the predefined target.

The Impella ECP is an investigational device limited to investigational use, and will be submitted for FDA approval in the next stages.


Copyright (c) 2024 CercleFinance.com. All rights reserved.